Table 1.
Anti-proliferate activity of PHA-767491 in multiple myeloma cell lines with diverse genetic and molecular features. The indicated established myeloma cell lines were treated with increasing amount of PHA-767491. Cell viability was examined by CellTiter Glo 48 h after drug treatment. The IC50 was calculated using GraphPad Prism.
| Cell Line | I⁰ Translocation | M-Spike | P53 Status | Copy Number (markers) | PHA-767491 IC50 (μM) |
|---|---|---|---|---|---|
| KMS-18 | t(4; 14) | IgG lambda | Not Known | 1.2 (613) | 1 |
| U-266 | Insertion IgH switch element on 11q13 | IgE lambda | Mutant [31,32] | 1.1 (614) | 1 |
| OCI-My5 | t(14; 16) | Not Known | WT and Mutant [33,34] | 2.0 (406) | 1.5 |
| RPMI-8226-Dox40 | t(14; 16) | IgG lambda | Mutant | Not Known | 2 |
| RPMI-8226-LR5 | t(14; 16) | IgG lambda | Deficient [32] | Not Known | 3.5 |
| MM1S | t(14; 16) | IgG lambda | WT [32] | 2.1 (337) | 2 |
| MM1R | t(14; 16) | IgG lambda | Not Known | 2.2 (336) | 1 |